Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Price Target at $3.86

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been given a consensus recommendation of “Moderate Buy” by the nine research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $3.8571.

A number of research firms have recently commented on RVPH. Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, October 4th. Benchmark dropped their price objective on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a report on Monday, September 15th. Maxim Group reduced their target price on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, August 15th. Chardan Capital initiated coverage on Reviva Pharmaceuticals in a research report on Monday, September 29th. They set a “buy” rating and a $2.00 target price for the company. Finally, D. Boral Capital restated a “buy” rating and issued a $2.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, October 28th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RVPH. Armistice Capital LLC purchased a new position in shares of Reviva Pharmaceuticals in the 2nd quarter valued at approximately $1,026,000. 683 Capital Management LLC acquired a new position in Reviva Pharmaceuticals during the 2nd quarter valued at approximately $381,000. Persistent Asset Partners Ltd lifted its stake in shares of Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after buying an additional 480,864 shares during the period. Geode Capital Management LLC grew its holdings in shares of Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares during the last quarter. Finally, Private Advisor Group LLC acquired a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at $191,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Price Performance

RVPH stock opened at $0.50 on Friday. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $4.28. The business has a 50 day simple moving average of $0.50 and a two-hundred day simple moving average of $0.59. The company has a market capitalization of $34.96 million, a price-to-earnings ratio of -0.78 and a beta of -0.03.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. Sell-side analysts anticipate that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.